marketupdatenews

SUBMITTED BY: marketupdatenews

DATE: July 5, 2022, 11:37 a.m.

FORMAT: Text only

SIZE: 3.5 kB

Raw Download

HITS: 359

Report
  1. Irritable Bowel Syndrome Treatment Market Regional Analysis, Market Segments and forecast 2027
  3. Market Overview:
  5. According to our latest study on “Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Product, and Distribution Channel,” the market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
  7. Get Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00006814/
  9. The healthcare sector witnessed SARS, H1N1, and other outbreaks in the past a few years. However, the severity of the COVID-19 outbreak has intensified due to its mode of transmission. North America has been witnessing an exponentially growing number of COVID-19 confirmed cases since its outbreak. The outbreak led to a chaotic situation in the medical industry across North American countries, leading to a dramatic rise in the demand for alternative medicines. The governments of various countries have been distributing the Irritable Bowel Syndrome (IBS) treatment medicines due to the rising COVID-19 cases. For instance, the Cuban government distributed homeopathic remedy PrevengHo-Vir to the geriatric and other vulnerable population. Therefore, Irritable Bowel Syndrome (IBS) treatment market is experiencing a positive impact of the COVID-19 pandemic owing to the rising demand for immunity booster medications.
  11. Based on product, the irritable bowel syndrome (IBS) treatment market is segmented into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. The linaclotide segment held the largest share of the market in 2020. Also, the same segment is estimated to register the highest CAGR in the market during the forecast period. The market growth for this segment is attributed to the key factors such as the increasing manufacturing of generic version of linaclotide and rising market consolidation for developing and commercializing linaclotide to treat IBS.
  13. Ironwood Pharmaceuticals, Inc., AbbVie., Sebela Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Alfasigma S.p.A., Astellas Pharma Inc., AstraZeneca, Synthetic Biologics, Inc., Bausch + Lomb Incorporated; and Lannett Company Inc are among the leading companies operating in the global irritable bowel syndrome (IBS) treatment market.
  15. Buy Now: https://www.theinsightpartners.com/buy/TIPRE00006814/
  17. The report segments global irritable bowel syndrome (IBS) treatment market as follows:
  19. By Type
  21. IBS with Diarrhea (IBS-D)
  22. IBS with Constipation (IBS-C)
  23. Mixed IBS (IBS-M)
  24. By Product
  26. Rifaximin
  27. Eluxadoline
  28. Linaclotide
  29. Lubiprostone
  30. Others
  31. By Distribution Channel
  33. Hospitals Pharmacies
  34. Drug Stores and Retail Pharmacies
  35. Online Pharmacies
  36. By Geography
  38. North America
  39. US
  40. Canada
  41. Mexico
  42. Europe
  43. France
  44. Germany
  45. UK
  46. Spain
  47. Italy
  48. Rest of Europe
  49. Asia Pacific (APAC)
  50. China
  51. India
  52. Japan
  53. Australia
  54. South Korea
  55. Rest of APAC
  56. Middle East and Africa (MEA)
  57. Saudi Arabia
  58. UAE
  59. South Africa
  60. Rest of MEA
  61. South and Central America (SCAM)
  62. Brazil
  63. Argentina
  64. Rest of SCAM
  67. Contact Us:
  69. If you have any queries about this report or if you would like further information, please contact us:
  71. Contact Person: Sameer Joshi
  73. E-mail: sales@theinsightpartners.com
  75. Phone: +1-646-491-9876
comments powered by Disqus